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Patients presenting with the coronavirus-2019 disease (COVID-19) may have a high risk of
cardiovascular adverse events, including death from cardiovascular causes. The long-term
cardiovascular outcomes of these patients are entirely unknown. We aim to perform a regis-
try of patients who have undergone a diagnostic nasopharyngeal swab for SARS-CoV-2
and to determine their long-term cardiovascular outcomes.
Study and design
This is a multicenter, observational, retrospective registry to be conducted at 17 centers in
Spain and Italy (ClinicalTrials.gov number: NCT04359927). Consecutive patients older than
18 years, who underwent a real-time reverse transcriptase-polymerase chain reaction (RT-
PCR) for SARS-CoV2 in the participating institutions, will be included since March 2020, to
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August 2020. Patients will be classified into two groups, according to the results of the RT-
PCR: COVID-19 positive or negative. The primary outcome will be cardiovascular mortality
at 1 year. The secondary outcomes will be acute myocardial infarction, stroke, heart failure
hospitalization, pulmonary embolism, and serious cardiac arrhythmias, at 1 year. Outcomes
will be compared between the two groups. Events will be adjudicated by an independent
clinical event committee.
Conclusion
The results of this registry will contribute to a better understanding of the long-term cardio-
vascular implications of the COVID19.
Introduction
Since Coronavirus disease 2019 (COVID-19) was first reported in China in late December
2019, it has spread rapidly worldwide, and it has become a pandemic affecting more than 200
countries. The exponential increase in the number of COVID-19 patients has overwhelmed
health-care systems in many countries across the world, with an unprecedented effect not only
on public health, but also on social and economic activities.
COVID-19 is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-
2). Currently, it is known that SARS-CoV-2 can produce a multi-system affectation, including
cardiovascular system [1]. This virus enters the cells by binding of the viral spike (S) protein to
angiotensin-converting enzyme 2 (ACE2) on the surface of the host cell. The ACE2 is highly
expressed in pulmonary tissues, but also in adult human hearts and endothelial cells, indicat-
ing an intrinsic susceptibility of these organs to a direct invasion of SARS-CoV-2. Further-
more, SARS-CoV-2 probably produces a downregulation in the ACE2 activity, reducing the
conversion of angiotensin II (Ang II) to Ang-(1–7). This may increase Ang II activity, which
continues stimulating renin-angiotensin-aldosterone system (RAAS) with deleterious effects
on heart and blood vessels [2–4].
An exacerbated inflammatory response with cytokine storm mediated through pathologic
T cells and monocytes leading to myocarditis, is another possible mechanism postulated to
explain cardiac injury due to COVID-19 [5, 6]. The pro-inflammatory environment and endo-
thelial dysfunction can also trigger the development of coagulopathy. Hypercoagulability leads
to coronary macro and microvascular thrombosis, and high incidence of thromboembolic
events in venous territories [7–9].
We currently know that myocardial injury is related with worse in-hospital prognosis in
COVID-19 patients [10–12]. A study of 26 patients recovered from COVID-19 evaluated with
cardiac resonance showed myocardial edema, fibrosis, and impaired right ventricle function
[13]. Available data suggests a probable implication on prognosis, but long-term implications
of COVID-19 on cardiovascular events are completely unknown.
The Cardiovascular COVID-19 (CV COVID-19) registry will aim to a better understanding
of the long-term cardiovascular implications in patients who had a SARS-CoV-2 infection.
Methods
Study design
It is a multicenter, observational, retrospective registry to be conducted at 17 centers in Spain
and Italy. This study is an investigator-initiated registry, and the promoter is the Fundació
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Clı́nic per a la Recerca Biomédica. Table 1 shows the list of enrolling centers and their princi-
pal investigators. The detailed list of the study staff is in the S1 File.
The Registry does not test clinical interventions, and individual patient care is entirely at
the discretion of treating clinicians.
This study adhered to the principles outlined in the Declaration of Helsinki. Approval was
given by the “Comité de Ética de la Investigación con medicamentos del Hospital Clı́nic de
Barcelona” (Ethics Committee for Drug Research of the Hospital Clı́nic of Barcelona) with the
registry HCB/2020/0457, on April 16, 2020. Given the registry’s anonymous characteristics
and the health alarm situation generated by the COVID-19 pandemic, written informed con-
sent was waived.
The study is registered at ClinicalTrials.gov (NCT number: NCT04359927).
Patient selection
Inclusion criteria are:
1. At least 18 years of age.
2. Patient who underwent a nasopharyngeal swab for real-time reverse transcriptase-polymer-
ase chain reaction (RT-PCR) for SARS-CoV2 between March 2020 and August 2020.
Exclusion criteria are:
Those with terminal diseases and a life expectancy <1 year before the diagnosis will be
excluded.
Patients will be classified into two groups: patients with confirmed COVID-19 (positive
RT-PCRT for SARS-CoV-2) and patients without COVID-19 (negative RT-PCR for SARS-
CoV2, and absence of absence of suspicious symptoms).
Data capture
Study data will be collected and managed using REDCap electronic data capture tools hosted
at Hospital Clı́nic of Barcelona (redcap.clinic.cat). REDCap (Research Electronic Data
Table 1. Centers and investigators.
Centers Investigators
Hospital Universitari Clı́nic de Barcelona Dr. Luis Ortega-Paz
Hospital Universitari Sagrat Cor Dr. Gabriela Bastidas
Hospital Universitari de Bellvitge Dr. Josep Gómez-Lara
Hospital Marqués de Valdecilla Dr. José Marı́a de la Torre
Hospital Universitario Juan Ramón Jiménez Dr. Antonio Gómez-Menchero, Dr. José Francisco Dı́az Fernández
Hospital Universitario La Princesa Dr. Fernando Alfonso
Hospital Universitari Vall d’Hebron Dr. Jordi Bañeras Rius
Hospital Clı́nico Universitario de Valladolid Dr. Ignacio Jesús Amat-Santos
Hospital Universitario de León Dr. Miguel Rodrı́guez-Santamarta
Hospital Universitario de Vigo Dr. Victor Alfonso Jimenez-Dı́az
Hospital Universitario Clı́nico San Carlos Dr. Nieves Gonzalo
Istituto Clinico Sant’Ambrogio Dr. Alfonso Ielasi
Azienda Ospedaliero-Universitaria di Ferrara Dr. Gianluca Campo
Hospital de Tortosa Verge de la Cinta Dr. Alberto Pernigotti
Ospedale Bolognini di Seriate Dr. Antonio Silvestro
Hospital Universitari Arnau de Vilanova Dr. Diego Fernández-Rodrı́guez
Hospital Universitari Joan XXIII Dr. Claudia Scardino
https://doi.org/10.1371/journal.pone.0255263.t001
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Capture) is a secure, web-based software platform designed to support data capture for
research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails
for tracking data manipulation and export procedures; 3) automated export procedures for
seamless data downloads to common statistical packages; and 4) procedures for data integra-
tion and interoperability with external sources.
An anonymized and predefined electronic Case Report Form (eCRF) developed by the
investigators will be filled by each participating center. The selected variables are oriented to
the cardiovascular risk factors, conditions, medications, and outcomes (Table 2). Moreover,
based on the current scientific literature, specific COVID-19 variable and treatment will be
also collected. Charlson Comorbidity Index (CCI) will be used to assess patient’s comorbidi-
ties. CCI is a validated index for predicting life expectancy at ten years, depending on the age
at which it is evaluated, and on the subject’s comorbidities [14]. The detailed eCRF format can
be seen in the S2 File.
All the data will be obtained from electronic records (medical history). If deemed necessary,
the investigator may check the patient vital status in the social national security database.
Clinical follow-up will be performed at 1-year. The flowchart and study timeline are
detailed in Fig 1.
Table 2. Data to be obtained in the timeline of the study.
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• DVT and PE
• Cardiac arrhytmias
• Bleeding









• Heart failure hospitalization
• PE
• Cardiac arrhytmias
ACS, acute coronary syndrome; DVT, deep venous thrombosis; Hs-cTnI, high sensitivity cardiac troponin I; NSAIDs, non-steroidal anti-inflammatory drugs; PE,
pulmonary embolism.
�Lowest values during hospitalization.
�Highest values during hospitalization.
https://doi.org/10.1371/journal.pone.0255263.t002
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Monitoring
Independent study monitors (Effice, Madrid, Spain) verified the adequacy of the follow-up
and events reported, conducting auditing in a random sample of 10% of all patients included.
All events were adjudicated and classified by an independent event adjudication committee
(S1 Table) blinded to the treatment groups by reviewing source documents (including angio-
grams) provided by each center (Barcicore Lab, Barcelona, Spain).
Outcomes and definitions
The primary outcome will be:
• Cardiovascular mortality at 1-year follow-up, defined according to the Academic Research
Consortium-2 [15].
The secondary outcomes will be:
• Myocardial infarction: defined according to the Academic Research Consortium-2 [15].
• Stroke: defined according to the Academic Research Consortium-2 [15].
• Heart failure hospitalization must be documented in the diagnosis of the hospitalization dis-
charge letter.
• Pulmonary embolism must be documented with a computed tomography.
Fig 1. Timeline of the study. Inclusion of the patients will be since March to August 2020. Analysis of the clinical outcomes will be performed in August
2021.
https://doi.org/10.1371/journal.pone.0255263.g001
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• Cardiac arrhythmias must be documented in the diagnosis of the hospitalization discharge
letter. Serious cardiac arrhythmias were defined as: bradycardia requiring intravenous medi-
cation or pacemaker, supraventricular tachycardia requiring intravenous medication or car-
dioversion, or ventricular tachycardia requiring intravenous medication or cardioversion.
• Major bleeding was defined as a type 3 of the Bleeding Academic Research Consortium
(BARC) or higher [16].
All the events will be independently adjudicated by a Clinical Events Committee. The Clini-
cal Event Committee (CEC) consists of cardiologists not participating in the trial. The CEC
members will be blinded to PCR COVID of the patient.
Statistical analysis plan
We did not estimate a precise sample size, due to lack of literature reports and we aim to get
the maximum numbers of patients possible.
Continuous variables will be presented as mean ± standard deviation. Categorical variables
will be reported as absolute number and percentage. Differences in proportions will be tested
with Chi-square test or Fishers exact test and differences in continuous variables will be tested
with a Student’s t-test. Kaplan-Meier method will be used to derive the event rates at follow-up
and to plot time-to-event curves. Patients not eligible for 1-year follow-up will be considered
at risk until the date of last contact, at which point they will be censored.
To determine the predictors of cardiovascular death, a Cox proportional hazards model will
be used together with the Wald test to compare the results between the groups (patients with
positive vs. negative RT-PCR for SARS-CoV-2).
All p-values will be two-sided and a value <0.05 will be considered statistically significant.
All data will be processed using the Statistical Package for Social Sciences, version 22 (SPSS
Inc., Chicago, IL, USA).
Discussion
In this multicenter, observational, retrospective registry, we aim of investigate the long-term
cardiovascular implications of COVID-19. Currently is known that the presence of myocardial
injury, vascular dysfunction and thrombosis in patients with COVID-19 have an important
role in the short-term prognosis in these patients [9]. Previous experience with the severe
acute respiratory syndrome coronavirus-1 (SARS-CoV-1) emerged in 2002, suggests that both
the underlying disease and its treatment could be associated with a worse cardiovascular prog-
nosis. In a study of 25 survivors of SARS-CoV-1, at 12 years of follow-up, altered lipid metabo-
lism was found [17]. Similarly, viral diseases such as influenza A are associated with increased
cardiovascular mortality after infection [18].
The focus of this registry will be on the cardiovascular outcomes, providing data not only
about cardiac ischemic events but also arrhythmias, cerebrovascular events and heart failure. It
should be highlighted that our findings will be applicable to any COVID19 patient, regardless
of the severity of the disease, as we will be including a consecutive population of patients with
COVID-19 infection. Confirmed cases will be evaluated and compared with those patients
who did not have COVID-19 infection. This approach will offer a greater security at the
moment of assessing study’s findings. This control group will help to minimize bias that would
arise if only COVID-19 patients were independently analyzed. Cox regression will help to dis-
tinguish the independent predictors for mortality among the patients of the study. However,
considering that a proportion of the SARS-CoV-2 infections can be asymptomatic, there can
be a degree of bias if the control patients (non-COVID-19 group) become infected but exhibit
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an asymptomatic disease during follow-up. Nevertheless, potential patients fulfilling these
characteristics can represent a minimal part of the sample size.
It is important to mention as strength of the study, that the events will be adjudicated by an
independent committee blinded to the patients’ treatment allocation and trial results. This will
guarantee a better evaluation of the study events.
Conclusion
The results of the CV COVID-19 registry will contribute to a better understanding of the short
and long-term implications of this disease. It will provide information about cardiovascular
mortality and cardiac events at one year of follow-up. Also, it will identify characteristics asso-
ciated with higher incidence of complications, defining a profile of COVID-19 patients with
worse prognosis.
Supporting information
S1 Table. List of committees and members.
(DOCX)
S1 File. List of all investigators of the involved centers.
(DOCX)
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Brugaletta.
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